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The assessment of defibrillation (DFT) efficacy has long been the standard of care during
defibrillator implantation. To ensure an acceptable DFT safety margin, early defibrillator
systems frequently required that the shock polarity and the location, type, or number of
electrodes had to be altered. Advances in defibrillator and lead technology have resulted in
lower and more consistent DFT thresholds in the range of 10 J, with an infrequent
requirement to modify the DFT system. Yet, one can make an argument for and against
continuation of DFT testing at the time of defibrillator implantation. The goal of this paper
is to address both the data that do support and the data that do not support continuation of
DFT testing at the time of device implantation. Scientifically, DFT testing should be
abandoned only when prospective evidence demonstrates that defibrillator implantation
without testing is as safe and has the same mortality benefits as implantation with testing. The
most attractive aspect of eliminating DFT efficacy testing is that more patients may have the
opportunity to be treated with this life-saving therapy. Perhaps there are alternative strategies
to improve accessibility to defibrillator therapy without possibly eroding its effectiveness. In
the end, will lives be saved or lost if we discontinue DFT efficacy testing and lower the barriers
to implantable defibrillator therapy? (J Am Coll Cardiol 2004;44:88–91) © 2004 by the
American College of Cardiology Foundationh
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rhe assessment of defibrillation (DFT) efficacy has long
een the standard of care during defibrillator implantation
1,2). To ensure an acceptable DFT safety margin, early
efibrillator systems frequently required that the shock
olarity and the location, type, or number of electrodes had
o be altered. Advances in defibrillator and lead technology
ave resulted in lower and more consistent DFT thresholds
n the range of 10 J, with an infrequent requirement to
odify the DFT system (3,4). Because DFT efficacy testing
dds time, possibly adds cost, and involves some morbidity,
t is fair to review the evidence and ask whether the
eliability of DFT with standard implantation techniques is
ufficient to preclude DFT testing at the time of defibrillator
mplantation.
See page 92
ISTORY OF DFT TESTING
efibrillation efficacy traditionally has been performed with
uccessive DFT attempts using approximately 20 J in a
evice that delivered 25 to 30 J (1,2). A safety margin of 10 J
as required for the implantation of the earliest defibrilla-
ors. The inventors and early researchers of the implantable
efibrillator selected 10 J for the safety margin based on the
aximum available energy of 25 J and on a few animal and
From the *Division of Cardiology, Washington Hospital Center, Washington,
C; and the †Division of Cardiology, University of Ontario, London, Ontario,
anada.
Manuscript received September 11, 2003; revised manuscript received Novemberg7, 2003, accepted November 24, 2003.uman studies that suggested early DFT systems would
enerally be effective with 15 J (Mower MM, personal
ommunication, 2003) (5,6). The initial implants required
uccessful DFT with the maximum device output of 25 J,
hich therefore assumed a 10-J safety margin (M. M.
ower, personal communication, 2003). The 10-J safety
argin was subsequently confirmed in patients with an
mplantable defibrillator (7) and validated as defibrillators
ere demonstrated to reduce mortality (8–11) and because
atients with inadequate DFT safety margins were thought
o have a higher mortality rate (12,13). As technology
mproved, DFT thresholds were substantially reduced.
ost studies of new DFT systems required documentation
f a 10-J safety margin, with only the rare study requiring
esting beyond documentation of an adequate safety margin
14). Today, our general impression is that only a small
ercentage of physicians do more than confirm a 10-J safety
argin at implant.
HE DFT SYSTEMS
urrent implantable defibrillator systems provide an average
FT threshold of 8 to 10 J. These systems use one or two
ntracavitary DFT electrodes while the defibrillator pulse
enerator functions as a subcutaneous electrode (active can).
nly in unusual cases does the DFT system need to be
odified to achieve adequate DFT efficacy, for example,
ith the addition of another subcutaneous DFT electrode,
eversal of shock polarity, and/or with the use of a pulse
enerator with greater delivered energy (15). The frequency
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July 7, 2004:88–91 To DFT Test or Not to DFT Testith which these approaches are used to achieve adequate
FT efficacy is probably around 5%.
ECHNIQUES FOR DETERMINING DFT EFFICACY
efibrillation efficacy may be assessed in various ways. The
ost time-honored approach confirms a 10-J safety margin.
onsiderably less frequently, a step-down DFT protocol
hat uses decrementing energy levels for subsequent DFT
ttempts until DFT fails or an abbreviated step-down
rotocol that is terminated after two or three DFT attempts
ave been used. Determining the upper limit of vulnerabil-
ty as an alternative to direct DFT testing has been proposed
16,17). The upper limit of vulnerability demonstrates DFT
fficacy by estimating the DFT threshold from the lowest
nergy level that will not induce ventricular fibrillation (VF)
ith a “shock on T” (16). Each of the aforementioned
echniques that assess DFT efficacy will identify the infre-
uent patient in whom modification of the DFT system is
equired to achieve an adequate DFT safety margin.
Documentation of DFT efficacy provides an additional
afety evaluation of the lead position and the system’s ability
o sense, detect, and defibrillate VF. The induction of VF at
he time of defibrillator implantation poses little risk.
lthough precise data are not available, the intraoperative
ortality rate is probably in the range of 0.1%.
FT TESTING OR NOT
hat is the rationale for abandoning DFT testing-
First, the probability of a high DFT threshold and a failed
mplant is quite small. Second, the majority of ventricular
rrhythmias treated by an implantable defibrillator are
entricular tachycardia. The cardioversion energy for ven-
ricular tachycardia is probably significantly less than the
FT energy required for VF (18). In addition, the proba-
ilistic nature of DFT suggests that shocks less than the
etermined threshold, when repeated several times, have
ome probability of success even in the much less likely
vent of VF (4,19). Thus, even the infrequent patient with
high DFT threshold who does receive a DFT system that
s incapable of defibrillating VF at the time of device
mplantation may not to succumb to an episode of VF.
ndeed, defibrillator testing is withheld in some patients
ith profound left ventricular dysfunction, a group where
FT testing is arguably the most necessary. Next, the
etermination of DFT efficacy requires additional anesthet-
cs, and the shocks themselves may cause hemodynamic
ompromise (20). Finally, DFT testing may be a barrier to
mplantable defibrillator therapy in regions with few or no
Abbreviations and Acronyms
DFT  defibrillation
VF  ventricular fibrillationlectrophysiologists. It may be argued that other physicians, tuch as those currently implanting pacemakers, would more
eadily implant defibrillators if not for the requirement of
FT testing.
hat are the arguments for continued DFT testing-
First, all the data supporting increased survival with
mplantable defibrillators were attained with some assess-
ent of DFT efficacy at implant (8 –11). Arguably, the
equirement for testing was essential in demonstrating
evice efficacy. Second, there is no doubt that some
atients receive a more effective DFT system because
FT testing is performed. For instance, patients with a
rank inability to defibrillate are identified, and corrective
easures such as the use of a higher energy device,
ddition of electrodes, or reversal of shock polarity can be
sed (15). Ensuring that the system provides effective
FT and appropriate sensing of VF is intuitively very
ompelling, although not proven to improve survival.
here are no data that specifically demonstrate increased
ortality among patients with high DFT thresholds.
pstein et al. (12) observed that 42% of patients with an
levated DFT threshold who were treated with an im-
lantable defibrillator died suddenly. However, the two-
ear mortality rate was 20%. An annual mortality rate in
n implantable defibrillator population from the early
990s of approximately 10% may not be considered
xcessive, and it may be possible that patients who cannot
e defibrillated easily have intrinsically higher mortality
ates independent of defibrillator usage. Third, an accu-
ate estimate of the DFT threshold should facilitate
rogramming of shocks to a multiple of the DFT
hreshold, allowing lower energy shocks (3,4). This may
esult in less syncope and near-syncope and improve
ost-shock hemodynamics (20). Finally, the medico-legal
mplications of an unexplained death or documented
ailure to defibrillate are uncertain. Arguably, failure by
he physician to verify DFT efficacy may be a compelling
rgument that the implant procedure fell below the
tandard of care, a position that would be supported by
any electrophysiologists.
hat evidence would be required to establish equiva-
ence or superiority of a strategy of no testing versus
urrent DFT testing? Data from a randomized trial would
robably be required. Patients undergoing defibrillator im-
lantation would be randomized to DFT testing or no DFT
esting. It seems obvious that mortality should be the
rimary end point, or at least a major component of the
rimary end point, if a composite primary end point was
eveloped. Factors such as cost and procedural complica-
ions can be readily assessed but are unlikely to be acceptable
s sole primary end points. To estimate the number of
atients required for a randomized mortality study, the first
ssumption is that 5% of patients will not be successfully
efibrillated with the maximum output of a standard device
hat uses the usual lead position and shock polarity. Second,
75% of this 5% of patients will receive appropriate
herapies after implant (i.e., 3.75% of the total number of
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To DFT Test or Not to DFT Test July 7, 2004:88–91atients who receive an implantable defibrillator). If 25% of
ppropriate shocks are for VF and represent excess mortal-
ty, then the rate of excess mortality as a result of not
ssessing DFT efficacy would be 25% of 3.75% of patients,
r about 1% of initial implants. If the usual death rate for
mplantable defibrillator patients is 10% per year, a reason-
ble estimate, the study population would need to differen-
iate between mortality rates of 10% and 11%. Using these
ssumptions, which probably overestimate the frequency of
igh DFT thresholds and the frequency of VF, approxi-
ately 29,000 patients would need to be randomized to
chieve a statistical power of 80%. Although different
ssumptions can be made and a creative study design can
educe the sample size, it is clear that such a study would
nvolve a large number of patients.
A looming question is who will do the implantation
rocedure with the study? If the goal is to demonstrate that
xperienced defibrillator implanters can safely and effectively
mplant a defibrillator without DFT efficacy testing, then
hese physicians should implant the devices and position the
eads. If the goal is to demonstrate that experienced pace-
aker implanting physicians without defibrillator implan-
ation experience can safely and appropriately implant defi-
rillators, then these physicians should participate in the
rial and at least perform the implants in the patients
andomized to implantation without DFT efficacy testing.
his would allow the study to test the hypothesis that
hysicians with pacemaker implantation experience, but not
efibrillator implantation experience, can implant defibril-
ators with an appropriate mortality rate.
ONCLUSIONS
he assessment of DFT efficacy at the time of implant has
ong been the standard of care. It is intuitively reasonable to
nsure that the system has an acceptable DFT safety margin
t the time of implant. One might ask simply whether the
ownsides of ensuring device sensing and DFT capability
re sufficient to discontinue this practice. DFT efficacy
esting may be minimally assessed with as few as one or two
nductions of VF with only rare complications. The exper-
ise involved in performing this task should not be outside
he capabilities for an implanting team involved in the care
f patients requiring these devices. With the evolution of
evices that defibrillate more efficiently and predictably, it is
air to ask whether initial DFT testing is still necessary.
cientifically, this question should be answered only with
rospective evidence that demonstrates at least equivalent
atient safety, equivalent mortality reduction, and cost
avings. Proponents of eliminating DFT testing need to
emonstrate the safety and benefits of such a strategy with
bjective evidence before this element of defibrillator im-
lantation is abandoned. The most attractive aspect of
liminating DFT efficacy testing is that more patients may
ave the opportunity to be treated with this life-saving
herapy. Perhaps there are alternate strategies to improveccessibility to defibrillator therapy without possibly eroding
ts effectiveness. In the end, will lives be saved or lost if we
iscontinue DFT efficacy testing and lower the barriers to
mplantable defibrillator therapy?
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